BioSpace News Archive

PhaseBio Pharmaceuticals, Inc. announced that results from the Phase 1 clinical trial of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, demonstrated that PB2452 provided immediate and sustained reversal of ticagrelor antiplatelet effects without report of drug-related serious adverse events.

The Nomination Committee has consisted of Axel Calissendorff, Chairman of the nomination committee, Lars Backsell, Johan Lannebo and Ossian Ekdahl.

This approval marks the first new initial treatment option for this difficult-to-treat type of lung cancer in more than 20 years.

Esperion, based in Ann Arbor, Mich., announced results from its Phase III Study 2 of bempedoic acid at the American College of Cardiology (ACC) annual meeting.

The company announced positive topline results from its Phase III EMPOWUR trial of viregron in patients with overactive bladder.

The Finnish Red Cross Blood Service offers free blood type tattoos to blood donors. The campaign raises interest towards blood donation and dismantles antiquated misconceptions around tattoos and blood donation.

Collaboration explores opportunities to set up antibiotic discovery and development platform and establish a joint pipeline of novel antibiotic assets

The FY19 Defense Appropriation provides $100 million to the Department of Defense Prostate Cancer Research Program to support innovative, high-impact prostate cancer research.

Sterna biologicals GmbH & Co. KG announced that the company held a Scientific Advisory Board meeting to evaluate the phase IIb clinical development program for SB012 in ulcerative colitis.

The FY19 Defense Appropriation provides $16 million to the Department of Defense Parkinson’ Research Program to support research to understand, prevent, diagnose, and treat Parkinson’s disease.